Fierce Biotech10d
GSK posts data on HIV assets vying for roles in 6-month combo
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
Fierce Healthcare3d
HHS may cut HIV prevention efforts at the CDC. Advocates fear changes will spike infections
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
BioSpace11d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Zacks Investment Research on MSN3d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Trump administration weighs major cuts to HIV prevention funding, WSJ reports
The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...
BioSpace13d
FDA Action Alert: GSK, Alnylam, Sanofi and More
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...